Swiss biopharmaceutical company
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva.[1] The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.[2]
History
Relief Therapeutics was founded in 2013 by Gael Hédou with the aim of developing new treatments for diseases with high unmet needs.[3] The company today considers itself the successor to Mondobiotech, which was founded in 2000 by Fabio Cavalli and Dorian Bevec.[4] Mondobiotech began research into Vasoactive intestinal peptide (VIP), a naturally occurring substance in humans that was first identified in the 1970s. They were granted US and European patents for a synthetic version of VIP known as aviptadil in 2006.[5]
On June 23, 2013, Mondobiotech merged with Italian pharmaceutical company Pierrel Research International to form a new Contract research organization known as Therametrics. On July 14, 2016, Therametrics merged with Relief Therapeutics to form Relief Therapeutics Holdings AG, which inherited all patents related to aviptadil.[6]
COVID-19 research
Aviptadil
In the wake of the COVID-19 pandemic, scientists at Relief conducted initial studies into the efficacy of RLF-100 in treating severe COVID-19 patients. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19.[7][8] In September 2020, Relief partnered with US-Israeli firm NRX Pharmaceuticals (formerly NeuroRx Inc) for the co-development of the drug and the co-ordination of US trials.[9] In April 2021, a reformulated version of aviptadil, known as Zyesami, was included in a National Institutes of Health (NIH) sponsored Phase 3 trial with the aim of testing aviptadil against remdesivir.[10] In May 2021, NRX submitted a request for an Emergency Use Authorization (EUA) to the US FDA for aviptadil's use in patients in intensive care.[11][12] On 7 October 2021 Relief Therapeutics filed a lawsuit against NRX Pharmaceuticals and its CEO Dr. Jonathan Javitt in the Supreme Court of the State of New York,[13] citing multiple alleged breaches of the collaboration agreement signed by the two companies for the co-development of aviptadil.[14]
On 4 November 2021 the FDA declined EUA for the drug, but committed to working with NRX to further develop it.[15] On 29 November 2021, NRX announced that data analysis from the NIH-sponsored Phase 3 trial showed a fourfold increase in survival at 60 days for patients administered with Zyesami (Aviptadil) vs those who received placebo.[16]
Sentinox
On 27 October 2021, Applied Pharma Research (APR), a wholly-owned subsidiary of Relief, announced positive interim data from its clinical trial of Sentinox, a nasal spray aimed at reducing the viral load of patients with COVID-19, in-turn reducing the transmissibility of the virus.[17]
Other research
In October 2021, Relief announced that its collaboration partner, Texas-based Acer Therapeutics, had successfully filed for a New Drug Application with US FDA for their drug ACER-001, for the treatment of Urea Cycle Disorders (UCDs) and Maple syrup urine disease.[18]
In September 2021, APR launched a chewable tablet for the treatment of Phenylketonuria, called PKU GOLIKE KRUNCH, in Germany and Italy.[19] APR are also developing Nexodyn, a drug which aids in the management of hard-to-heal ulcers requiring long periods of treatment.[20]
Relief is actively developing RLF-100 for non-COVID-19 related acute and chronic lung diseases, such as Pulmonary sarcoidosis.[21]
